CoChat

Oral tobramycin in ulcerative colitis: effect on maintenance of remission

LOBO, A. J., BURKE, D. A., SOBALA, G. M., AXON, A. T. R. · 1993 · Alimentary Pharmacology & Therapeutics
Cited by 74

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

SUMMARY: Oral tobramycin for 7 days has been shown to be of benefit as an adjunct to conventional medication in acute ulcerative colitis. Eighty‐one patients (40 who had received tobramycin; 41 placebo) who had been enrolled in a double‐blind placebo‐controlled trial of this drug in acute disease were subsequently followed to determine whether this short‐term benefit persisted. Relapse was defined as a liquid stool frequency of three times daily with rectal bleeding. Results were analysed by the log‐rank test on Kaplan‐Meier survival curves. Treatment failure was defined as a lack of response by the end of the acute trial period, or subsequent relapse. In a second analysis, only those entering remission at the end of the acute trial were considered, and followed to relapse. Although at the start of the follow‐up period significantly fewer patients in the tobramycin group had failed (failed: tobramycin 9, placebo 24; not failed tobramycin 31; placebo 17;P= 0.001), the failure‐free survival curves subsequently converged and did not differ significantly. After 1 and 2 years, the failure‐free survival rates were 40% (S.E. = 7.8%) and 20% (S.E. = 6.3%) for the tobramycin group and 24% (S.E. = 6.7%) and 12% (S.E. = 5.1%) for the placebo group. When only those entering remission were considered, there was no significant difference in the relapse rates in the two groups. Benefit from tobramycin is therefore short‐lived and may reflect short‐term changes in the faecal flora.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.1993.tb00084.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 74

Metadata

Authors
LOBO, A. J., BURKE, D. A., SOBALA, G. M., & AXON, A. T. R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
1993-04
Volume
7
Issue
2
Pages
155-158
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2060859971
Cited by
74
References
1
FWCI
0.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral tobramycin in ulcerative colitis: effect on maintenance of remission. https://app.cochat.ai/papers/10.1111/j.1365-2036.1993.tb00084.x
The paper
LOBO, A. J., BURKE, D. A., SOBALA, G. M., & AXON, A. T. R. (1993). Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.1993.tb00084.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.